Business Wire

Probiotics for Corals Boost Resilience, Help Prevent Mortality

18.8.2021 10:00:00 EEST | Business Wire | Press release

Share

A new study shows probiotics to be helpful protagonists in boosting coral health and preventing mortality in the face of environmental stressors, such as warming oceans and changing climate conditions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210818005016/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

KAUST Marine Scientist Dr. Raquel Peixoto administers probiotics, or Beneficial Microorganisms for Corals (BMC), to Pocillopora verrucosa coral in controlled aquarium environments. (Photo: KAUST)

Published in Science Advances, the study details research conducted by the Federal University of Rio de Janeiro, Brazil, in collaboration with the Red Sea Research Center at King Abdullah University of Science and Technology (KAUST). It is the first of its kind to show that Beneficial Microorganisms for Corals (BMC) can protect bleached corals from death, by stimulating immune processes that help them rebuild their microbiome environment and offset “post-heat stress disorder” symptoms driven by thermal stress.

The scientists created a probiotic using microbes derived from the coral itself, selecting strains with traits deemed likeliest to boost resilience. They isolated, plated and studied hundreds of bacteria strains for their potential to serve as BMCs. They inoculated two groups of corals in controlled environments—those with probiotics and those with a placebo, exposing both to the same degree of thermal stress. Probiotics increased the stability and survivorship in the algae-coral host relationship by more than 40%.

Dr. Raquel Peixoto, lead author and KAUST marine scientist, said, “Whereas all corals initially bleached and showed signs of stress, those with BMCs survived and returned to their original state, with results similar to corals that had not been exposed at all. Corals without BMCs sustained damage or died. The holistic formula equipped the corals with hearty traits for buffering and surviving heat trauma.”

Contributing author Dr. Chris Voolstra, reef genomicist and big data specialist, said, “The study is remarkable for demonstrating ‘genetic reprogramming,’ meaning, microbes prompt the coral to make beneficial changes at the genetic level rather than superimpose their functions onto the host. This is a key understanding about the mechanisms underlying coral probiotics that was not known before.”

The study received funding from the Great Barrier Reef Foundation’s Out of the Blue Box Reef Innovation Challenge, for new ideas to protect coral reefs, and was supported by the Tiffany & Co Foundation.

Great Barrier Reef Foundation Managing Director Anna Marsden said, “Pioneering science such as this provides hope for the future of the Great Barrier Reef and coral reefs globally, which are coming under increasing pressure from climate change.”

Read the full article here.

*Source: AETOSWire

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Najdat Boukarroum
Najdat.boukarroum@kaust.edu.sa

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hisense Delivers 38% Sales Uplift in Western Europe Markets With NIQ’s AI-Powered Market Intelligence6.5.2026 06:00:00 EEST | Press release

NIQ (NYSE: NIQ), a global leader in consumer intelligence, today shared new learnings from its long-standing collaboration with Hisense, a leading global brand in home appliances and smart technologies. Using NIQ’s AI‑powered market intelligence, Hisense has accelerated international expansion, improved local market decision-making, and delivered measurable growth across more than 20 key markets and 12+ categories. The case study demonstrates how AI‑driven insights help global brands move faster, localize better, and compete more effectively in complex markets. The Challenge As Hisense expanded internationally, it faced rising complexity across global markets. Consumer preferences differed sharply across regions such as Western Europe, Eastern Europe, and Latin America, making a one‑size‑fits‑all approach ineffective. NIQ’s AI‑powered intelligence delivered the local market depth needed to guide investment, refine product positioning, and identify the features that mattered most in eac

KILL Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 05:14:00 EEST | Press release

Samsung Bioepis Co., Ltd. requests that their press release NewsItemId: 20260505353718 “Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)” be killed. The release was issued prematurely by Samsung Bioepis Co., Ltd. The news release will be updated and redistributed in the near future, incorporating further information on SB27.

Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 02:00:00 EEST | Press release

Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, double-blind, three-arm, parallel group, multicenter clinical trial demonstrated pharmacokinetic bioequivalence of SB27 (pembrolizumab) to the reference product Keytruda. Initiated in January 2024, Phase 1 study is being conducted in four countries, and is expected to be completed by November 2026.2 The study assessed pharmacokinetics, efficacy, safety, and immunogenicity of SB27, EU-sourced Keytruda, and US-sourced Keytruda in patients with stage II or IIIA non-small cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy. 163 participants were randomized to receive SB27, EU-sourced Keytruda, or US-sourced Keytruda every 3 weeks, maximum 18 cycles over about 51 weeks, and blood samples were collected. The preliminary pharmacokinetic evaluation indicates t

Megaport Launches Built-In DDoS Protection Enabling On-Demand Network Resilience6.5.2026 01:00:00 EEST | Press release

Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport DDoS Protection. This new, built-in security capability for Megaport Internet allows customers to filter malicious traffic directly within the Megaport network rather than routing it through a separate or external service, for mission-critical uptime without introducing additional latency or routing complexity. As enterprises increasingly migrate to distributed cloud environments, traditional DDoS mitigation has struggled to keep pace with cloud and distributed infrastructure adoption. Standard ISP solutions often resort to dropping all traffic and taking the service offline to protect the network, while external third-party providers force a "security detour" that reroutes traffic through public infrastructure, introducing significant latency and complexity. Megaport DDoS Protection removes these challenges by integrating fabric-native protection directl

IFF Reports First Quarter 2026 Results5.5.2026 23:23:00 EEST | Press release

IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks the balance of the year and gives us the confidence to reaffirm our full-year 2026 financial guidance ranges in an uncertain environment. At the same time, w

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye